These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32936345)

  • 41. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease.
    Watanabe K; Matsumoto T; Hisamatsu T; Nakase H; Motoya S; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):542-549.e1. PubMed ID: 29104132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
    Cohen RD; Lewis JR; Turner H; Harrell LE; Hanauer SB; Rubin DT
    Inflamm Bowel Dis; 2012 Jan; 18(1):10-6. PubMed ID: 21456032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
    Tournier Q; Paul S; Williet N; Berger AE; Veyrard P; Boschetti G; Le Roy B; Killian M; Phelip JM; Flourie B; Nancey S; Roblin X
    Aliment Pharmacol Ther; 2021 Jun; 53(11):1190-1200. PubMed ID: 33872404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.
    Goss SL; Klein CE; Jin Z; Locke CS; Rodila RC; Kupper H; Burmester GR; Awni WM
    Clin Ther; 2018 Feb; 40(2):309-319. PubMed ID: 29402521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.
    Mazor Y; Almog R; Kopylov U; Ben Hur D; Blatt A; Dahan A; Waterman M; Ben-Horin S; Chowers Y
    Aliment Pharmacol Ther; 2014 Sep; 40(6):620-8. PubMed ID: 25039584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution.
    Kamiya K; Karakawa M; Komine M; Kishimoto M; Sugai J; Ohtsuki M
    J Dermatol; 2019 Mar; 46(3):199-205. PubMed ID: 30672612
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.
    Zhang ZM; Li W; Jiang XL
    Gut Liver; 2016 Mar; 10(2):262-74. PubMed ID: 26780088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
    Hisamatsu T; Kato S; Kunisaki R; Matsuura M; Nagahori M; Motoya S; Esaki M; Fukata N; Inoue S; Sugaya T; Sakuraba H; Hirai F; Watanabe K; Kanai T; Naganuma M; Nakase H; Suzuki Y; Watanabe M; Hibi T; Nojima M; Matsumoto T;
    J Gastroenterol; 2019 Oct; 54(10):860-870. PubMed ID: 31041545
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis.
    Skrabl-Baumgartner A; Seidel G; Langner-Wegscheider B; Schlagenhauf A; Jahnel J
    Arch Dis Child; 2019 Mar; 104(3):246-250. PubMed ID: 30026253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.
    Pariente B; Pineton de Chambrun G; Krzysiek R; Desroches M; Louis G; De Cassan C; Baudry C; Gornet JM; Desreumaux P; Emilie D; Colombel JF; Allez M
    Inflamm Bowel Dis; 2012 Jul; 18(7):1199-206. PubMed ID: 22127789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of Early Postinduction Adalimumab Exposure With Subsequent Clinical and Biomarker Remission in Children with Crohn's Disease.
    Rinawi F; Ricciuto A; Church PC; Frost K; Crowley E; Walters TD; Griffiths AM
    Inflamm Bowel Dis; 2021 Jun; 27(7):1079-1087. PubMed ID: 32978946
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical utility of serum concentrations of adalimumab as predictor of treatment adherence.
    Sáez Belló M; Llopis Salvia P; Alegre Sancho JJ; Paredes Arquiola JM; Asencio Muñoz MDC; Climente Martí M
    Reumatol Clin (Engl Ed); 2020; 16(1):32-37. PubMed ID: 29500118
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea.
    Seo H; Ye BD; Song EM; Lee SH; Chang K; Lee HS; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK
    Dig Dis Sci; 2017 Oct; 62(10):2882-2893. PubMed ID: 28822006
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.
    Billiet T; Dreesen E; Cleynen I; Wollants WJ; Ferrante M; Van Assche G; Gils A; Vermeire S
    Am J Gastroenterol; 2016 Oct; 111(10):1438-1445. PubMed ID: 27481307
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
    Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J
    Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry.
    Tapete G; Bertani L; Pieraccini A; Lynch EN; Giannotta M; Morganti R; Biviano I; Naldini S; Mumolo MG; De Nigris F; Calella F; Bagnoli S; Minciotti M; Maltinti S; Rentini S; Ceccarelli L; Lionetti P; Milla M; Costa F
    Inflamm Bowel Dis; 2022 Jan; 28(1):62-69. PubMed ID: 33570142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
    Sharma S; Eckert D; Hyams JS; Mensing S; Thakkar RB; Robinson AM; Rosh JR; Ruemmele FM; Awni WM
    Inflamm Bowel Dis; 2015 Apr; 21(4):783-92. PubMed ID: 25723614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study.
    Kamat N; Kedia S; Ghoshal UC; Nehra A; Makharia G; Sood A; Midha V; Gupta V; Choudhuri G; Ahuja V
    Indian J Gastroenterol; 2019 Feb; 38(1):44-54. PubMed ID: 30645725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
    Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.